Project summary review: Developing and testing a new miniature device to monitor Pancreatic Cancer Treatment

Provide feedback on a project summary looking to develop a tiny device to help doctors track how pancreatic cancer cells respond to treatment, and potentially improve patient care and reduce unnecessary side effects.

The project

Pancreatic cancer poses a significant treatment challenge due to its resistance to chemotherapy and identifying patients who will respond well to chemotherapy remains crucial. This project aims to understand the behaviour that cancer cells undergo during treatment and will look closely at the cells dependence on a component called uridine when there is little glucose present.

Dr Anguraj Sadanandam, Dr Burak Temelkuran and Dr Salzitsa Anastasova are undertaking an innovative project which looks to develop a miniature device that can track levels of uridine, glucose, oxygen and acidity levels in real time in cancer cells during treatment and then test these devices in mice. If successful, this approach could potentially revolutionise patient care as it promises personalised treatment assessment for pancreatic cancer patients, offering a less invasive alternative to traditional biopsies. This project prioritises patient needs, aiming to improve outcomes and minimise unnecessary chemotherapy toxicity.

Dr Anguraj Sadanandam at the Institute of Cancer Research, Dr Burak Temelkuran and Dr Salzitsa Anastasova at Imperial College London are looking to apply for a Pancreatic Cancer UK Interdisciplinary Treatment Grant to fund their research. They are looking for feedback on their project summary which aims to develop a tiny device to help doctors track how pancreatic cancer cells respond to treatment, and potentially improve patient care and reduce unnecessary side effects.

Next steps

No scientific background or prior experience is needed to take part in this opportunity.

If you would like to give your feedback on this project, please contact the Research Team (research@pancreaticcancer.org.uk) quoting the involvement reference ‘ITG Sadanandam’. We will then email you the lay summary and any specific questions Dr Anguraj Sadanandam, Dr Burak Temelkuran and Dr Salzitsa Anastasova would like you to consider. Please return your responses to the research team by Monday 13th May 2024.